WuXi AppTec’s Corporate Venture Fund was among the participants in a series A round disclosed as the precision medicine startup emerged from stealth.
Precision medicine developer D3 Bio launched in China yesterday with $200m in series A funding from investors including pharmaceutical firm WuXi AppTec’s Corporate Venture Fund.
Private equity firm Boyu Capital, Singaporean government-owned investment firm Temasek and venture capital firms Matrix Partners China and Sequoia Capital China also contributed to the round.
D3 Bio has assessed the breadth of medical treatments to identify areas with unmet need where it can target its drug pipeline. It is working on cancer and immunology…
